Literature DB >> 25368118

Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.

Kay O Johswich1, Shannon E McCaw2, Lea Strobel3, Matthias Frosch3, Scott D Gray-Owen4.   

Abstract

Neisseria meningitidis asymptomatically colonizes the human upper respiratory tract but is also the cause of meningitis and severe septicemia. Carriage or disease evokes an immune response against the infecting strain. Hitherto, we have known little about the breadth of immunity induced by natural carriage of a single strain or its implications for subsequent infectious challenge. In this study, we establish that transgenic mice expressing human CEACAM1 support nasal colonization by a variety of strains of different capsular types. Next, we nasally challenged these mice with either of the N. meningitidis strains H44/76 (serogroup B, ST-32) and 90/18311 (serogroup C, ST-11), while following the induction of strain-specific immunoglobulin. When these antisera were tested for reactivity with a diverse panel of N. meningitidis strains, very low levels of antibody were detected against all meningococcal strains, yet a mutually exclusive "fingerprint" of high-level cross-reactivity toward certain strains became apparent. To test the efficacy of these responses for protection against subsequent challenge, CEACAM1-humanized mice exposed to strain 90/18311 were then rechallenged with different N. meningitidis strains. As expected, the mice were immune to challenge with the same strain and with a closely related ST-11 strain, 38VI, while H44/76 (ST-32) could still colonize these animals. Notably, however, despite the paucity of detectable humoral response against strain 196/87 (ST-32), this strain was unable to colonize the 90/18311-exposed mice. Combined, our data suggest that current approaches may underestimate the actual breadth of mucosal protection gained through natural exposure to N. meningitidis strains.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25368118      PMCID: PMC4288889          DOI: 10.1128/IAI.02495-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Multiple mechanisms of phase variation of PorA in Neisseria meningitidis.

Authors:  A van der Ende; C T Hopman; J Dankert
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 2.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

3.  Identification of proteins of Neisseria meningitidis induced under iron-limiting conditions using the isobaric tandem mass tag (TMT) labeling approach.

Authors:  Peter van Ulsen; Karsten Kuhn; Thorsten Prinz; Harald Legner; Peter Schmid; Christian Baumann; Jan Tommassen
Journal:  Proteomics       Date:  2009-04       Impact factor: 3.984

Review 4.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

5.  Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.

Authors:  L G Milagres; M C Gorla; M C Rebelo; D E Barroso
Journal:  FEMS Immunol Med Microbiol       Date:  2000-08

6.  Serological correlates of protection against meningococci in a cohort of university students, before and during an outbreak of serogroup C infection.

Authors:  Jeannette N Williams; Graeme R Jones; Myron Christodoulides; John E Heckels
Journal:  J Infect Dis       Date:  2003-04-15       Impact factor: 5.226

7.  Transgenic mice expressing human transferrin as a model for meningococcal infection.

Authors:  Maria-Leticia Zarantonelli; Marek Szatanik; Dario Giorgini; Eva Hong; Michel Huerre; Florian Guillou; Jean-Michel Alonso; Muhamed-Kheir Taha
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

8.  Many carried meningococci lack the genes required for capsule synthesis and transport.

Authors:  Heike Claus; Martin C J Maiden; Rainer Maag; Matthias Frosch; Ulrich Vogel
Journal:  Microbiology       Date:  2002-06       Impact factor: 2.777

Review 9.  Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.

Authors:  Johan Holst; Diana Martin; Richard Arnold; Concepcion Campa Huergo; Philipp Oster; Jane O'Hallahan; Einar Rosenqvist
Journal:  Vaccine       Date:  2009-05-28       Impact factor: 3.641

10.  Characterization of humoral and cellular immune responses elicited by meningococcal carriage.

Authors:  K Robinson; K R Neal; C Howard; J Stockton; K Atkinson; E Scarth; J Moran; A Robins; I Todd; E Kaczmarski; S Gray; I Muscat; R Slack; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more
  3 in total

Review 1.  Et tu, Neisseria? Conflicts of Interest Between Neisseria Species.

Authors:  Rene Baerentsen; Christoph M Tang; Rachel M Exley
Journal:  Front Cell Infect Microbiol       Date:  2022-06-24       Impact factor: 6.073

2.  Complement C5a Receptor 1 Exacerbates the Pathophysiology of N. meningitidis Sepsis and Is a Potential Target for Disease Treatment.

Authors:  Johannes B Herrmann; Marcel Muenstermann; Lea Strobel; Alexandra Schubert-Unkmeir; Trent M Woodruff; Scott D Gray-Owen; Andreas Klos; Kay O Johswich
Journal:  mBio       Date:  2018-01-23       Impact factor: 7.867

Review 3.  Targeting bacterial transferrin and lactoferrin receptors for vaccines.

Authors:  Anthony B Schryvers
Journal:  Trends Microbiol       Date:  2022-02-26       Impact factor: 18.230

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.